Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide+Sintilimab+Bevacizumab in Advanced Extrapulmonary Neuroendocrine Carcinoma
NCT07518602Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Mar 2026
- Primary completion
- Mar 2028
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tucidinostat, sintilimab, bevacizumab in extrapulmonary neuroendocrine carcinoma (EPNEC), sponsored by Sun Yat-sen University. Started Mar 2026; status: recruiting.
02
Drugs
tucidinostatsintilimabbevacizumab
03
Conditions
extrapulmonary neuroendocrine carcinoma (EPNEC)
Beyond the preview
Go deeper on NCT07518602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07518602.